Avance advises Verso Fund II Ky and the other shareholders of Ginolis Oy in the sale of the company to CELLINK AB (publ) for a cash and debt-free purchase price of EUR 70 million.
Founded in 2010, Ginolis is a leading life sciences robotics and diagnostics automation company providing workflows and solutions for medical and diagnostics companies around the world. Ginolis offers a range of highly innovative, modular, robotics systems for precise manufacturing of multiplex assays, lateral flow PoC-tests, and medical devices. Ginolis is currently both manufacturing and also providing systems for manufacturing of Covid-19 tests in the United States and Europe.
The transaction is expected to be completed in the beginning of March.